GPCR Binding, Signaling, and Pharmacology: Key Concepts (Orthosteric vs Allosteric, Bias, KD/Ki/EC50, Radioligand Binding, and Clinical Relevance)

Receptors: binding sites, structure, and basic signaling

  • Orthosteric vs. allosteric binding sites
    • A receptor has a primary active spot (the orthosteric site) where the endogenous ligand binds.
    • Other sites are allosteric, modulating receptor conformation and signaling.
  • Conformational dynamics and biased signaling
    • Agonists induce conformational changes in GPCRs that bias downstream signaling pathways.
    • The receptor’s 3D conformation determines which downstream partners are engaged (e.g., G proteins vs. arrestins).
    • Concept aligns with structure–activity relationships: binding alters topology, influencing downstream events.
  • GPCR signaling architecture (at a glance)
    • Activated GPCR leads to separation of the G protein into activated subunits:
    • Gα subunit (various families) and the βγ dimer.
    • Different α subtypes couple to different effectors (see below).
    • Classic downstream effectors include:
    • Adenylyl cyclase (AC) → cAMP → PKA pathway.
    • Phospholipase C (PLC) → IP3 and DAG → Ca2+ signaling and PKC.
    • Ion channels modulation and various kinases.
  • Arrestin pathways and alternative signaling
    • β-arrestin can scaffold signaling cascades independent of G proteins.
    • Biased signaling can favor G protein signaling or arrestin signaling depending on the ligand and receptor context.
    • Example notes: β-arrestin–mediated signaling has been explored in retinitis pigmentosa with experimental drugs; carvedilol is discussed as a biased ligand in some contexts.
    • Arrestin recruitment often accompanies receptor phosphorylation by GRKs and can lead to receptor internalization.
  • Constitutive (basal) activity and inverse agonism
    • Some receptors exhibit constitutive activity (basal signaling without ligand).
    • Inverse agonists reduce this basal activity, effectively producing the opposite of constitutive activation.
    • Example discussed: antihistamines like olopatadine as inverse agonists in some systems.
  • Full vs. partial agonists; tissue- and species-dependence
    • Full agonist: maximal efficacy when binding receptor; reaches near 100% of a system’s maximal response.
    • Partial agonist: efficacy is <100% even at full receptor occupancy; can act as functional antagonist in the presence of a full agonist.
    • The same ligand can be a full agonist in one tissue and a partial agonist in another due to differences in receptor–effector coupling (tissue specificity) and possibly species differences.
    • Example: a drug acting as a full agonist in the dorsal raphe but only a partial agonist in the median raphe due to differing signaling context.
  • Examples that illustrate the concepts
    • Serotonin receptor family (5-HT): endogenous ligand serotonin acts on multiple subtypes (e.g., 5-HT1, 5-HT2, etc.). In experiments, a ligand like 5-CT can yield different maximal responses across brain regions (dorsal raphe vs medial raphe) due to tissue-specific coupling.
    • DMT (a psychedelic) is a partial agonist at 5-HT2A in the context shown, while other ligands (endogenous or synthetic) can show full efficacy in other contexts.
    • Endogenous cannabinoids vs synthetic cannabinoids (e.g., WIN55, WIN 2-0, CP 55,940) show differing intrinsic activities at the CB1 receptor: delta-9-THC tends to be a partial agonist; synthetic cannabinoids can be full agonists with higher efficacy, explaining stronger or more dramatic effects.
    • Buprenorphine (partial opioid agonist) vs naloxone (competitive antagonist) illustrate therapeutic use of partial agonists and antagonists in opioid dependence and overdose management.
  • Terminology recap (core terms you’ll see on exams)
    • Receptor occupancy: fraction of receptors bound by ligand at a given concentration.
    • Efficacy (efficacy, maximal effect): how well a ligand triggers a downstream response once bound.
    • Potency: how much drug is needed to achieve a given effect (often related to EC50).
    • Spare receptors: tissue-specific receptor reserve allowing full responses at less-than-full receptor occupancy.
    • Intrinsic activity (often denoted α): fraction of maximal response produced per receptor occupied; α = 1 for a full agonist, α < 1 for partial agonists; α can be used in simplified models to relate occupancy to response.
  • Key distinction: affinity vs efficacy
    • Affinity determines how tightly a ligand binds the receptor (occupancy at given concentration).
    • Efficacy determines how effectively receptor occupancy produces a signal.
    • Both contribute to overall potency (EC50) and maximal response (Rmax). In some models, high affinity can compensate for lower efficacy, and vice versa.
  • Model context: why these concepts matter in neural signaling
    • Brain signaling involves two main receptor types:
    • Ligand-gated ion channels (ionotropic receptors; e.g., nicotinic acetylcholine receptors, GABA_A receptors, glycine, AMPA/NMDA).
    • G protein–coupled receptors (GPCRs; metabotropic).
    • The lecture emphasizes GPCR signaling in the brain, with downstream coupling to adenylyl cyclase, phospholipase C, and other effectors, and the added complexity of arrestin pathways.

Receptor pharmacology: binding, affinity, and occupancy

  • KD (dissociation constant)
    • Definition: K<em>D=k</em>extoffkextonK<em>D = \frac{k</em>{ ext{off}}}{k_{ ext{on}}}
    • KD is a direct measure of ligand–receptor affinity: the smaller the KD, the higher the affinity.
    • In radioligand binding assays with tissue membranes, KD is determined from saturation binding curves using radiolabeled ligand.
  • Occupancy and binding curves
    • Fractional occupancy (RD/Rtotal) is given by: f</em>extocc=[D]KD+[D]f</em>{ ext{occ}} = \frac{[D]}{K_D + [D]}
    • As [D] increases, occupancy approaches 1 (saturation).
  • EC50 and potency
    • EC50 is the concentration of an agonist that produces 50% of the maximal response (Rmax) in a given assay.
    • In functional assays, potency is linked to how much drug is required to elicit the response; EC50 is a practical readout of that potency.
  • Ki (inhibitor constant)
    • Ki measures the affinity of an unlabeled ligand used as an inhibitor to displace a radiolabeled ligand.
    • Standard relation (Schild equation):
      K<em>i=IC</em>501+[L]KDK<em>i = \frac{IC</em>{50}}{1 + \frac{[L]}{K_D}}
      where:
    • IC50 is the inhibitor concentration producing 50% displacement of radioligand binding.
    • [L] is the radioligand concentration used in the assay.
    • K_D is the dissociation constant of the radiolabeled ligand.
    • Ki is a constant for a given receptor–ligand pair under those assay conditions; it reflects binding affinity, not whether the ligand is an agonist or antagonist.
  • Affinity vs potency in practice
    • Higher affinity (lower KD or KI) generally lowers the dose needed to achieve a given occupancy and can increase potency, but efficacy (intrinsic activity) also limits the maximal response.
    • A ligand can have high affinity but low efficacy (partial agonist) or high efficacy but moderate affinity.
  • Radioligand binding as a nonfunctional readout
    • Binding assays quantify occupancy, not downstream signaling.
    • They require separating specific binding from nonspecific binding, typically by subtracting nonspecific binding from total binding to obtain specific binding.
  • Practical notes from the lecture on radioligand binding
    • Tissue sources: animal tissues (e.g., pig brain) were historically used to obtain receptor-rich membranes.
    • Specific vs nonspecific binding: essential to obtain accurate occupancy data.
    • Receptor subtyping: differences in ligand affinity across receptor subtypes can define receptor families and subtypes.

GPCR signaling: structure, subunits, and effectors

  • Architecture of a GPCR
    • Seven transmembrane domains; extracellular ligand-binding domain and intracellular regions coupling to G proteins.
    • The receptor couples to heterotrimeric G proteins consisting of Gα, Gβ, and Gγ subunits.
  • G protein subtypes and effectors (typical examples mentioned)
    • Gα_s → activates adenylyl cyclase → ↑cAMP → PKA pathway.
    • Gα_i/o → inhibits adenylyl cyclase → ↓cAMP; can also regulate ion channels.
    • Gα_q/11 → activates phospholipase C (PLC) → IP3 and DAG → Ca2+ release and PKC activation.
    • Gβγ subunits can also regulate ion channels and kinases.
  • Receptor activation and downstream signaling
    • Ligand binding induces GDP-GTP exchange on Gα; Gα-GTP and Gβγ dissociate and engage downstream effectors.
    • Signaling leads to a cascade of intracellular events that produce functional responses (e.g., changes in neuronal excitability, gene expression).
  • Arrestin and receptor desensitization
    • Phosphorylation of activated GPCRs by GRKs promotes β-arrestin binding.
    • Arrestin uncouples the receptor from G proteins and can mediate receptor internalization and alternative signaling cascages.
  • Bias in GPCR signaling
    • Biased agonism occurs when different ligands stabilize receptor conformations that preferentially recruit G proteins or β-arrestin pathways.
    • This bias can be modulated by ligand structure, receptor subtype, tissue context, and perhaps receptor phosphorylation patterns.
  • Examples referenced in the lecture
    • Adenylyl cyclase as a major Gαs effector; PLC as a major Gαq effector; ion channels can be regulated by Gβγ and Gα subunits.
    • The discussion includes the notion that a single receptor can engage multiple signaling routes depending on the bound ligand and downstream coupling efficiency.

Ligand-gated ion channels vs GPCRs (brief contrast)

  • Ligand-gated ion channels (ionotropic receptors)
    • Directly open ion channels in response to ligand binding (e.g., nicotinic ACh receptor, GABA_A receptor, glycine receptor, AMPA/NMDA receptors).
    • Tend to produce fast synaptic transmission.
  • GPCRs (metabotropic receptors)
    • Indirect signaling through G proteins and other pathways (arrestin, kinases).
    • Slower, modulatory effects that can engage multiple second messenger systems.
  • The lecture notes that nicotinic ACh receptors and other ligand-gated channels can have constitutive activity in some contexts, and that the broader pharmacology of receptors includes both receptor families.

Receptor subtypes, endogenous ligands, and receptor discovery

  • Receptors and endogenous ligands
    • Opioid receptors were identified before endogenous opioids were understood; later, endogenous ligands like dynorphin and enkephalins were discovered.
    • Cannabinoid receptors were identified before the endogenous cannabinoids (endocannabinoids) were characterized.
  • Receptor cloning and orphan receptors
    • Cloning allowed receptor subtypes to be studied in controlled cellular contexts and helped define selectivity profiles for ligands.
    • Orphan receptors are receptors without identified endogenous ligands; many are still under investigation as potential drug targets.
  • Receptor families highlighted
    • Serotonin (5-HT) receptors; nicotinic ACh receptors; GABA receptors (GABAA and GABAB); glycine receptors; cannabinoid receptors; histamine receptors; dopamine transporters and other uptake systems.
  • Transporters as pharmacological targets and indirect agonism
    • Neurotransmitter transporters (e.g., SERT, DAT, NET) clear neurotransmitters from the synapse.
    • Inhibitors of transporters (e.g., SSRIs like fluoxetine) act as indirect agonists by increasing synaptic neurotransmitter levels.
    • The lecture notes that transporter inhibitors can show receptor- or transporter-specific affinity profiles (Ki) analogous to receptor ligands.

Drug specificity, affinity, and off-target effects (examples and interpretation)

  • What Ki tells you
    • Ki reflects how tightly an unlabeled ligand binds to the receptor in competition with a labeled ligand.
    • Ki is a measure of affinity, not mechanism (agonist vs antagonist) or efficacy.
  • Examples of receptor–drug interactions and affinities
    • D4 receptor ligands vs other receptors (e.g., D2 or others) show Ki values that illustrate receptor selectivity; many ligands have nanomolar Ki values for multiple receptor types, so absolute specificity is rare.
    • α1 adrenergic receptor ligands (e.g., prazosin) show varying Ki across α1 subtypes; achieving a 100-fold selectivity is typically the aim for a useful drug to minimize off-target effects.
    • β1 adrenergic receptor ligands show affinities that can be substantial (e.g., some beta blockers or agonists display meaningful affinity), yet selectivity remains a challenge due to overlapping receptor family profiles.
  • Receptors vs transporters: cross-target considerations
    • Some drugs affect both receptors and transporters (e.g., antidepressants or psychostimulants) and thus have mixed pharmacology.
    • In drug development and pharmacology, screening for off-target effects on transporters (e.g., SERT, NET, DAT) as well as receptors is standard practice.
  • Practical takeaway for specificity
    • In practice, researchers look for a large difference in affinity across targets (often aiming for at least a 100-fold difference) to assert functional selectivity.
    • Small differences (e.g., 10-fold) may yield off-target effects at therapeutic doses; specificity is not absolute in biological systems.
  • Real-world examples discussed
    • Prazosin (α1 antagonist) and other α1 ligands show high affinity for α1 subtypes but often with incomplete selectivity among α1A vs α1D subtypes, illustrating the challenge of achieving perfect selectivity.
    • Chlorpromazine (a dibenzo-diazepine phenothiazine) shows activity at several receptors (e.g., 5-HT receptors and D4 receptors), illustrating multi-target pharmacology.
    • Propranolol (β receptor blocker) vs drugs with mixed affinities demonstrates how drugs with off-target effects can still be clinically useful but require careful management.
  • Takeaway about selectivity and receptors
    • No drug is perfectly specific; understanding affinity (KD, Ki) and functional efficacy (agonist vs antagonist vs inverse agonist) helps explain both therapeutic effects and side effects.

Clinical relevance and applications (examples mentioned)

  • Opioid system in addiction and overdose management
    • Buprenorphine: a partial μ-opioid receptor agonist used for opioid dependence management; provides analgesia with lower abuse potential and a ceiling effect.
    • Naloxone: a competitive antagonist used to reverse opioid overdose by blocking μ receptors; can precipitate withdrawal if opioid exposure remains.
  • Nicotine addiction treatment
    • Chantix (varenicline): a partial agonist at α4β2 nicotinic receptors; helps reduce withdrawal symptoms while blocking some rewarding effects of nicotine.
  • Other clinical notes
    • Antihistamines like olopatadine can act as inverse agonists, reducing basal histamine signaling.
    • SPICE (synthetic cannabinoids) often act as full agonists at CB1 receptors, sometimes producing more intense or atypical effects than Δ9-THC, which tends to be a partial agonist in many systems.
  • Therapeutic strategy: partial agonists as antagonists
    • Partial agonists can function as antagonists in the presence of full agonists by occupying receptors with sub-maximal efficacy, thereby dampening the full agonist response.
    • This property is exploited in therapies such as buprenorphine for opioids and varenicline for nicotine.

Equations and key formulas to memorize

  • Receptor occupancy (fraction bound by drug)
    • f<em>extocc=[D]K</em>D+[D]f<em>{ ext{occ}} = \frac{[D]}{K</em>D + [D]}
  • Dissociation constant (affinity)
    • K<em>D=k</em>extoffkextonK<em>D = \frac{k</em>{ ext{off}}}{k_{ ext{on}}}
  • Radioligand binding competition (Ki from IC50)
    • K<em>i=IC</em>501+[L]KDK<em>i = \frac{IC</em>{50}}{1 + \frac{[L]}{K_D}}
    • Here, [L] is the concentration of the radiolabeled ligand used in the assay; K_D is its dissociation constant.
  • Functional potency and efficacy (simplified occupancy–response relation)
    • Fractional efficacy with occupancy: (simplified model)
    • E=E<em>extmaximes(extintrinsicactivityimesf</em>extocc)=E<em>extmaximes(extαimes[D]K</em>D+[D])E = E<em>{ ext{max}} imes \bigl( ext{intrinsic activity} imes f</em>{ ext{occ}} \bigr) = E<em>{ ext{max}} imes \bigl( ext{α} imes \frac{[D]}{K</em>D + [D]} \bigr)
    • α = intrinsic activity; α = 1 for a full agonist; α < 1 for a partial agonist.
  • Dose–response shape in non-log vs log scale
    • On a non-log scale, the response is hyperbolic (Michaelis–Menten type): maximal binding at high occupancy.
    • On a log concentration scale, the dose–response appears sigmoidal; EC50 is the concentration for 50% of the maximal response.
  • Signaling readouts and GTP binding (GPCR activation)
    • Functional readout can be measured by GTP binding to the Gα subunit, reflecting G protein activation.
    • This is a direct functional assay to assess efficacy beyond simple binding.

Quick glossary (relevant for exams)

  • Orthosteric site: primary ligand-binding site at which endogenous ligand binds.
  • Allosteric site: secondary site that modulates receptor function when bound.
  • Biased agonism: ligand-induced receptor signaling favors one downstream pathway over another (e.g., G protein vs β-arrestin).
  • Constitutive activity: basal receptor activity in the absence of ligand.
  • Inverse agonist: ligand that reduces constitutive activity.
  • Full agonist: ligand producing maximal receptor response.
  • Partial agonist: ligand that produces sub-maximal response, even at full occupancy.
  • Spare receptors: receptor reserve; maximal response achieved without full receptor occupancy.
  • KD: dissociation constant; affinity measure for receptor binding.
  • Ki: inhibition constant; binding affinity of an unlabeled inhibitor in competition assays.
  • EC50: concentration giving 50% of maximal functional response; defines potency in a given assay.
  • Emax/Rmax: maximal observable response in a system.
  • Receptor reserve and tissue context: affinity and efficacy interact with tissue-specific coupling to produce observed responses.
  • G protein vs arrestin pathways: distinct, sometimes biased, downstream signaling routes after GPCR activation.

Summary takeaways for your exam

  • Understanding receptor pharmacology requires linking occupancy (KD, f_occ) to functional outcomes (EC50, Emax, α).
  • Bias, constitutive activity, inverse agonism, and spare receptors add layers of complexity to predicting drug effects across tissues.
  • Radioligand binding is a foundational technique to measure receptor affinity and occupancy; Ki and IC50 are central concepts, with Ki derived from IC50 via the Schild equation.
  • GPCR signaling is not limited to G proteins; arrestin pathways and receptor internalization add important signaling and regulatory dimensions.
  • Real-world drug examples illustrate how these concepts play out in medicine (e.g., naloxone vs buprenorphine, Chantix, antihistamine inverse agonists, SPICE cannabinoids).